4D Molecular Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $85.2 | $<0.1 | $20.7 | $3.1 | $18.0 |
| Operating income | -$159.5 | -$187.8 | -$112.9 | -$110.0 | -$71.3 |
| Net income | -$140.1 | -$160.9 | -$100.8 | -$107.5 | -$71.3 |
| Cash Flow Statement | |||||
| Free cash flow | -$109.6 | -$138.4 | -$78.6 | -$98.2 | -$78.2 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Shares outstanding 52.3M · Free float 74.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.